Walter Van Dyck

Walter studies idea emergence or how inventions come about and transform into innovations. During the last five years he coached the emergence of over a hundred of innovative ideas in global and multinational companies active in life sciences, smart systems, clean tech and their combinations using ‘Entrepreneurial Boot Camp’ active learning formats.

As Associate professor of Technology & Innovation Management at Vlerick Business School, he counsels and lectures about technology and innovation management across Europe, US and Asia with global companies like Johnson & Johnson’s Janssen Pharmaceutica, IMEC and NXP Semiconductors and as - Visiting Professor at Peking University. His team does extensive academic and business research in innovation ecosystem emergence, corporate venturing and IP-based business modelling using case studies and computer simulation-based research methods.   



Expert in
Strategic Innovation and R&D Management
Ideation in Science- and Technology-Based Ecosystems
Corporate Venturing and Intrapreneurship
Technology and Ecosystem Emergence
Technology- and IP-based Business Modelling
Life Sciences Management
Healthcare management

Profile

Professor Walter Van Dyck is Associate professor of Technology & Innovation Management at Vlerick Business School. He is Partner and member of the Academic Committee as Chairman of the Technology & Operations Management Area. He is also the Director of the Vlerick Healthcare Management Centre.

He obtained a Doctorate of Business Administration with the highest honours from Cranfield University, School of Management (UK), a BA and MA from the Royal Military Academy Brussels, specialising in electronics and telecom, and an MBA from Vlerick. Prior to joining academia, he was Senior Strategy Consultant with PricewaterhouseCoopers and IBM in the fields of R&D and innovation management, predominantly active in global pharmaceutical and biotech companies.

 

Publications

Articles in refereed journals with impact

  • Stremersch S. Van Dyck W.  2009. Marketing of the life sciences: a new framework and research agenda for a nascent field. Journal of Marketing, 73(July): 4-30.

Articles in other (un)refereed journals

  • Neels L. Van Dyck W.  2016. The price of success? Pharmaceutical IP and global healthcare: a positive alliance. Pharma Times Magazine, (May): 16-17.

  • Van Dyck W. Cardoen B.  2015. Personalized medicine: time to invest more in our health. The Clinical Services Journal, (February): 34-35.

  • Cumps B. Van Dyck W.  2014. Innovation in Financial services - Beyond the red castle. Global banking and finance review, (March)

  • Van Dyck W.  2014. The future of M&A in the pharmaceutical industry: Promoting or stifling innovation?. Finance Monthly, (June): 26-27.

  • Van Dyck W.  2012. Building and leveraging your ecosystem to spark innovation-based growth. Ivey Business Journal, 76(2): 7-9.

  • Van Dyck W. Gassull D. Vértes G. Prateek J. Palaniappan M. Schulthess D. Tambuyzer E. Hudson R. Moran N.  2012. Unlocking the value of personalised healthcare in Europe—breast cancer stratification. Health Policy and Technology, 1(2): 63-68.

  • Van Dyck W. Gassull D. Vértes G. Prateek J. Palaniappan M. Schulthess D. Tambuyzer E. Hudson R. Moran N.  2012. Acute coronary syndrome: what is the cost-effectiveness of prevention, point-of-care technology and telemonitoring?. Health Policy and Technology, 1(3): 173-177.

  • Leten B. Van Dyck W.  2012. Corporate venturing: Strategies and success factors. Review of Business and Economic Literature, 57(4): 242-243.

  • Van Dyck W. Allen P.  2006. Pharmaceutical Discovery as a Complex system of decisions: the case of front-loaded experimentation. Emergence: Complexity & Organization, 8(3): 40-56.

Book Chapters

  • Van Dyck W. Cumps B.  2016. The sharing economy demystified: Entrepreneurial platforms as engines of economic growth. In: Ed. Le Droit des Affaires en Evolution. Tome 27: L’ Economie du Futur – Le Futur de l’Economie: Institut des Juristes D’ Entreprise Bruylant.

  • Van Dyck W. Aelbrecht T.  2010. Going beyond the pill: business transformation through corporate venturing at Janssen Pharmaceutica. In: Silberzahn P. Van Dyck W. The balancing act of innovation (pp. 233-249).

  • Van Dyck W.  2004. Introducing advanced technology in pharmaceutical R&D: The need for a new paradigm?. Festel Capital.

  • Van Dyck W. Van Landeghem H.  1997. CIM invoeren in de praktijk: een kwestie van strategie. In: Ed. CIM Praktijkboek: Computer Integrated Manufacturing in België, een praktische handleiding gebaseerd op reële gevalstudies (pp. 21-44). Academia Press.

  • Van Dyck W.  1997. DAIKIN Europe: CIM ter ondersteuning van een JIT concept. In: Ed. CIM Praktijkboek: Computer Integrated Manufacturing in België, een praktische handleiding gebaseerd op reële gevalstudies Academia Press.

  • Van Dyck W.  1997. Het Europees distributiecentrum van Lee Europe. In: Ed. CIM Praktijkboek: Computer Integrated Manufacturing in België, een praktische handleiding gebaseerd op reële gevalstudies Academia Press.

Books

  • Silberzahn P. Van Dyck W.  2010. The balancing act of innovation. LannooCampus.

Conference Presentations

  • Van Dyck W. Geldof T.  2016. Defining Real World product performance using survival analysis and supervised machine learning. Paper presented at International Society for Pharmacoeconomics and Outcomes research ISPOR 19th Annual European Conference, Vienna, Austria.

  • Van Dyck W. Stokking A. Devoldere B. Stolwijk C. van der Horst T.  2016. Fieldlab as organizational form to overcome the valley of death. Paper presented at Strategic Management Society, SMS 36th Annual Conference, Berlin, Germany.

  • Baert C. Meuleman M. Debruyne M. Van Dyck W.  2012. A dynamic learning perspective of portfolio entrepreneurship in nascent markets. Paper presented at RENT XXVI conference: Research in Entrepreneurship and small business, November 21-23, Lyon, France.

Conference Proceedings

  • Van Dyck W.  2005. Predictive performance of front-loaded experimantation strategies in pharmaceutical discovery. 

  • Van Dyck W.  2004. Hoe kan Discovery de slaagkansen in Klinische Ontwikkeling bevorderen?. Utrecht:

  • Van Dyck W.  2004. Predictive performance of front-loaded experimentation strategies in pharmaceutical discovery. Manchester:

  • Van Dyck W.  2003. On Target 2010 - the future of medicines. 

  • Van Dyck W.  2002. Managing complexity in fuzzy front-end innovation: The need for a paradigm shift?. Cranfield:

Doctoral dissertation

  • Van Dyck W.  2005. Predictive Performance of Front-Loaded Experimentation Strategies in Pharmaceutical Discovery: A Bayesian Perspective. 

Research reports

  • Van Dyck W. De Grève J. Schots R. Awada A. Geldof T.  2016. The Future of Access to Innovative Medicines in Cancer Therapy: Towards Conditional Dialogue Fostering Affordable Therapeutic Innovation. (86 p.)

  • Van Dyck W. Geldof T.  2015. Oncology horizon scanning project. Healthcare Management Centre. (93 p.)

  • Boënne M. Robberecht R. Van den Bergh J. Goeman F. Costers N. Van Dyck W.  2015. Flanders DC open innovation bootcamps: hoe kunnen bootcamps bijdragen tot open innovatie bij en tussen KMO's - lessen uit de praktijkervaring. Flanders DC. (63 p.)

  • Van Dyck W. Denayer B. Reymer A. Boënne M.  2015. Emerging business models for additive manufacturing. Vlerick Business School. (47 p.)

  • Van Dyck W. Cardoen B. Neels L.  2014. White paper: it's time to invest more in our health. Healthcare Management Centre. (21 p.)

  • Van Dyck W. Gassull D. Vértes G. Jain P.  2012. Health for all, care for you: Unlocking the value of personalized healthcare in Europe. 

  • Stremersch S. Van Dyck W.  2009. Marketing of the life sciences: a new framework and research agenda for a nascent field. 

  • Van Dyck W. Fraser H.  2005. Transforming Industrialization.